FDA Priority Review

FDA Priority Review is one of the agency’s four expedited programs for drugs and biologics addressing serious conditions — alongside Breakthrough Therapy designation, Fast Track, and Accelerated Approval. Unlike the other three, which primarily shape the development program leading up to an application, Priority Review acts directly on FDA’s review clock for a completed marketing application: it shortens the agency’s goal for completing a first review cycle from 10 months to 6 months.

Eligibility criteria

FDA classifies an application for Priority Review when it determines the drug, if approved, would provide a significant improvement in the safety or effectiveness of the treatment, diagnosis, or prevention of a serious condition, compared with the standard of care already available. FDA’s own guidance describes several ways a sponsor can demonstrate significant improvement, including evidence of increased effectiveness in treating, preventing, or diagnosing a condition, elimination or substantial reduction of a treatment-limiting adverse reaction, documented enhancement of patient compliance likely to improve serious outcomes, or evidence of safety and effectiveness in a new subpopulation. Both original applications (New Drug Applications and Biologics License Applications) and efficacy supplements to an already-approved product can qualify.

The 6-month review clock

Priority Review and Standard Review are the two review-timeline goals FDA sets under the Prescription Drug User Fee Act (PDUFA). A Standard Review application carries a 10-month goal from the filing date for FDA to complete its first review cycle; a Priority Review application carries a 6-month goal. Priority Review shortens FDA’s internal target, not the scientific bar for approval — the underlying application still has to meet the same substantive safety and effectiveness standards FDA applies to any marketing application, and Priority Review classification does not guarantee an approval decision, only a faster goal date for reaching one.

How the designation happens

Priority Review differs procedurally from Fast Track and Breakthrough Therapy designation, both of which sponsors formally request and FDA grants earlier in development, often years before an application is filed. Priority Review classification is instead typically determined by FDA’s review division at the time it files the application, based on the significant-improvement criteria above, though a sponsor can and often does make the case for Priority Review directly in its submission cover letter. There is no separate standalone designation request comparable to a Breakthrough Therapy request; the classification attaches to the application itself once filed.

Priority Review vs. Fast Track, Breakthrough Therapy, and Accelerated Approval

All four expedited programs address serious or life-threatening conditions, but each intervenes at a different point:

• Fast Track is requested during development and facilitates earlier, more frequent FDA interaction plus eligibility for rolling review of a future application.
• Breakthrough Therapy designation is requested during development, based on preliminary clinical evidence of substantial improvement on a clinically significant endpoint, and adds intensive FDA guidance on the whole development program.
• Accelerated Approval is a pathway letting FDA approve a drug based on an effect on a surrogate or intermediate clinical endpoint reasonably likely to predict clinical benefit, with confirmatory trials required after approval.
• Priority Review acts only on the review clock for a completed marketing application — 6 months instead of 10 — and does not itself change development requirements or the approval standard.

A single product frequently accumulates more than one of these across its lifecycle: for example, a candidate might carry Breakthrough Therapy designation through development and then also receive Priority Review classification once its application is filed, because meeting Breakthrough Therapy’s evidentiary bar often supports a significant-improvement case for Priority Review too. The two are related in practice but remain distinct programs with distinct criteria and distinct points in the process where they apply.

Priority Review vs. the Priority Review Voucher program

Priority Review is easy to conflate with the Priority Review Voucher (PRV) program, but they are different mechanisms. Priority Review is a classification an application earns on its own merits, under the significant-improvement criteria above, and it applies only to that application. A Priority Review Voucher is a separate, transferable incentive awarded only under the rare pediatric disease or tropical disease PRV statutory programs; a company that holds a voucher can apply it to a completely different, otherwise-unqualifying future application — its own or one it acquires by purchasing the voucher from another company. In short: Priority Review is a review-timeline outcome tied to one application’s own qualifying merits; a PRV is a tradable asset that can import that same 6-month outcome onto an unrelated application later.

Why this matters for research administration

For research administrators and regulatory affairs staff supporting sponsor-investigators, spin-outs, or institutional IND/IDE holders, knowing whether a candidate product plausibly meets the significant-improvement bar for Priority Review affects timeline planning for site activation, budget cycles tied to an anticipated approval date, and how a submission’s cover letter and briefing materials are framed. Because Priority Review is generally determined at filing rather than requested years in advance like Breakthrough Therapy or Fast Track, it is less something an administrative office tracks as an early-stage milestone and more a factor built into the regulatory strategy for the marketing application itself, coordinated closely with regulatory affairs and clinical development leads.